Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Journal of Cardiology

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.amjcard.2011.06.054PMID 21855836PMCID PMC3196048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

  2013cited by this paper
• Red and Processed Meat Consumption and Risk of Incident Coronary Heart Disease, Stroke, and Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2010cited by this paper
• The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.

  2010cited by this paper
• Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

  2009cited by this paper
• Effects of Methotrexate on Plasma Cytokines and Cardiac Remodeling and Function in Postmyocarditis Rats

  2009cited by this paper
• Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.

  2008cited by this paper
• Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.

  2008cited by this paper
• Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone

  2008cited by this paper
• The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.

  2008cited by this paper
• Cardiovascular Involvement in General Medical Conditions

  2007cited by this paper
• Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis.

  2007cited by this paper
• Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis.

  2007cited by this paper
• Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study

  2006cited by this paper
• Patterns of cardiovascular risk in rheumatoid arthritis

  2006cited by this paper
• Antirheumatic drug use and the risk of acute myocardial infarction.

  2006cited by this paper
• Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.

  2006cited by this paper
• Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.

  2005cited by this paper
• Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis

  2005cited by this paper
• Inflammatory markers and the risk of coronary heart disease in men and women.

  2004cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

  2002cited by this paper
• Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

  2002cited by this paper
• Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

  2000cited by this paper
• Safety of low dose methotrexate in elderly patients with rheumatoid arthritis

  2000cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis.

  1999cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial.

  1990cited by this paper
• Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritis

  1990cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Cause of death in rheumatoid arthritis.

  1984cited by this paper

• The prevalence of coronary artery disease in rheumatoid arthritis patients in Palestine: a cross-sectional study

  2026cites this paper
• Evaluation of serial cardiovascular magnetic resonance monitoring and immunosuppressive therapy in predicting outcomes in systemic sclerosis

  2026cites this paper
• Connecting to improve drug discovery

  2026cites this paper
• Arterial Thrombosis in Severe Ulcerative Colitis: A Case-Based Narrative Review of Current Evidence

  2026cites this paper
• Cardiovascular risk in psoriatic arthritis: How can we manage it?

  2025cites this paper
• Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study

  2025cites this paper
• Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review

  2025cites this paper
• Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention

  2025cites this paper
• The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties

  2025influential citation
• Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarction

  2025cites this paper
• Positron Emission Tomography Imaging in Vasculitis.

  2025cites this paper
• Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry

  2025cites this paper
• The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs.

  2025cites this paper
• Metotrexato e leflunomida ainda têm seu lugar no tratamento da artrite reumatoide?

  2025cites this paper
• Effectiveness of Tildrakizumab in the Long‐Term Treatment of Plaque Psoriasis: A Retrospective, Multicenter Analysis Over 76 Weeks

  2025cites this paper
• CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS- A COMPREHENSIVE REVIEW OF MECHANISMS, ASSESSMENT, AND MANAGEMENT

  2025cites this paper
• Innovative drug discovery for cardiovascular metabolic inflammation diseases

  2025cites this paper
• Psoríase e risco cardiovascular: fatores associados e protetores

  2025cites this paper
• Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence

  2025influential citation
• Novel glycogen-based materials for scavenging cationic antimicrobial peptides.

  2025cites this paper
• Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study

  2025cites this paper
• Cardio-rheumatology: present and future. Part II

  2025cites this paper
• Psoriasis and cardiovascular risk: associated and protective factors

  2025cites this paper
• Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

  2025cites this paper
• Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials

  2025cites this paper
• Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary

  2024cites this paper
• JAK-Inhibitors – A Story of Success and Adverse Events

  2024cites this paper
• Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care

  2024cites this paper
• Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study.

  2024cites this paper
• Cardiovascular Risk in Rheumatoid Arthritis: Considerations on Assessment and Management

  2024cites this paper
• Nanophytosomal Gel of Heydotis corymbosa (L.) Extract against Psoriasis: Characterisation, In Vitro and In Vivo Biological Activity

  2024cites this paper
• Chronic inflammation and vascular cell plasticity in atherosclerosis

  2024cites this paper
• Blood Pressure Changes During Methotrexate Treatment: Results from a Randomized Placebo-Controlled Trial Among Patients with Cardiovascular Risk.

  2024cites this paper
• Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment

  2024cites this paper
• Factors associated with change in arterial stiffness in patients with rheumatoid arthritis: the JointHeart study

  2024cites this paper
• Cardiovascular event in a cohort of rheumatoid arthritis patients in Castilla-La Mancha: Utility of carotid ultrasound.

  2024cites this paper
• Formulation, Evaluation and Optimization of Acitretin Loaded Transethosomes for the Management of Psoriasis

  2024cites this paper
• The Future of Hypertension Pharmacotherapy: Ongoing and Future Clinical Trials for Hypertension.

  2024cites this paper
• Methotrexate, blood pressure and arterial function in rheumatoid arthritis: study protocol.

  2024cites this paper
• Atherosclerosis and inflammation: therapeutic targets and ways of correction

  2024cites this paper
• The Association Between Psoriasis and Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis of Observational Studies

  2024cites this paper
• Dermal Delivery of Hypericum perforatum (L.)Loaded Nanogel: Formulation to Preclinical Psoriasis Assessment.

  2024cites this paper
• Methotrexate and the Risk of Dementia: A Two-Sample Mendelian Randomization Study

  2024cites this paper
• Unlocking the Mysteries of Epicardial Adipose Tissue: Implications of Cardiometabolic Syndrome

  2024cites this paper
• Unraveling the Pleiotropic Role of High-Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases

  2024cites this paper
• Rheumatoid arthritis and cardiovascular comorbidities

  2023cites this paper
• Chronic rheumatologic disorders and cardiovascular disease risk in women

  2023cites this paper
• Review on Psoriasis Disease

  2023cites this paper
• The actions of methotrexate on endothelial cells are dependent on the shear stress-induced regulation of one carbon metabolism

  2023cites this paper
• New-onset atrial fibrillation in seropositive rheumatoid arthritis: association with disease-modifying anti-rheumatic drugs treatment.

  2023cites this paper
• Exercise therapy for improving cardiovascular health in rheumatoid arthritis

  2023cites this paper
• Factors associated with secondary coronary artery disease in rheumatoid arthritis patients: A systematic review and meta-analysis based on observational studies.

  2023cites this paper
• Sex-specific differences in cardiovascular risk factors and implications for cardiovascular disease prevention in women.

  2023cites this paper
• Role of Inflammatory Cytokines in Rheumatoid Arthritis and Development of Atherosclerosis: A Review

  2023cites this paper
• THE CORRELATION OF EXPRESSION OF DIFFERENTIAL DRUG-RESISTANT PROTEINS AND INFLAMMATORY CYTOKINES IN COLLAGEN INDUCED ARTHRITIS MODEL

  2023cites this paper
• Association of Cardiovascular Risks in Rheumatoid Arthritis Patients: Management, Treatment and Future Perspectives

  2023cites this paper
• Protocol for rheumatoid arthritis complicated with cardiovascular damage treated with Guanxining tablet with a randomized controlled trial

  2023cites this paper
• Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease

  2023cites this paper
• Update on Obesity in Psoriasis Patients

  2023cites this paper
• Positron Emission Tomography Imaging in Vasculitis.

  2023cites this paper
• Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets

  2023cites this paper
• Vascular health in subjects with rheumatoid arthritis: assessment of endothelial function indices and serum biomarkers of vascular damage

  2023cites this paper
• Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus

  2023cites this paper
• Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis

  2023cites this paper
• Targeting inflammation to reduce recurrent stroke

  2023cites this paper
• Cardiac health in rheumatoid arthritis: a Doppler perspective on steroids and methotrexate

  2023cites this paper
• Methotrexate & Rheumatoid Arthritis Associated Atherosclerosis: A Narrative Review of Multidisciplinary Approach for Risk Modification by the International Board of Experts.

  2023cites this paper
• Evento cardiovascular en una cohorte de pacientes con artritis reumatoide en Castilla-La Mancha, utilidad de la ecografía carotídea

  2023cites this paper
• Dyslipidemia in rheumatoid arthritis: the possible mechanisms

  2023cites this paper
• Subclinical carotid atherosclerosis: role of inflammation, cholesterol, hypertensive load and sex in rotational shift work in the Arctic

  2023cites this paper
• The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”

  2023cites this paper
• Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases

  2023cites this paper
• Multifunctional Nanoparticles Co-Loaded with Perfluoropropane, Indocyanine Green, and Methotrexate for Enhanced Multimodal Imaging of Collagen-Induced Arthritis.

  2022cites this paper
• Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

  2022cites this paper
• Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.

  2022cites this paper
• The management of cardiovascular disease risk in patients with rheumatoid arthritis

  2022cites this paper
• Sex-differential downregulation of methotrexate on plasma viscosity and whole blood viscosity in psoriasis

  2022cites this paper
• Managing Cardiovascular Risk in Patients with Rheumatic Disease.

  2022cites this paper
• Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?

  2022cites this paper
• Targeting the Residual Cardiovascular Risk by Specific Anti-inflammatory Interventions as a Therapeutic Strategy in Atherosclerosis.

  2022cites this paper
• Related Risk Factors and Treatment Management of Psoriatic Arthritis Complicated With Cardiovascular Disease

  2022cites this paper
• Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation.

  2022cites this paper
• Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions.

  2022cites this paper
• Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications.

  2022cites this paper
• Recent issues in JAK inhibitor safety: perspective for the clinician

  2022cites this paper
• Inflammation as a mechanism and therapeutic target in peripheral artery disease.

  2022cites this paper
• Greenspace, Inflammation, Cardiovascular Health, and Cancer: A Review and Conceptual Framework for Greenspace in Cardio-Oncology Research

  2022influential citation
• Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease

  2022cites this paper
• Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review

  2022cites this paper
• Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies

  2022cites this paper
• Multiple dissecting intracranial and extracranial aneurysms in rheumatoid arthritis: a rare case

  2022cites this paper
• IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis

  2022cites this paper
• Ultrasound-guided chemoradiotherapy of breast cancer using smart methotrexate-loaded perfluorohexane nanodroplets.

  2022cites this paper
• Drug repurposing in cardiovascular inflammation: Successes, failures, and future opportunities

  2022cites this paper
• Metabolic Abnormalities, Cardiovascular Disease, and Metabolic Syndrome in Adult Rheumatoid Arthritis Patients: Current Perspectives and Clinical Implications

  2022cites this paper
• The cardiometabolic conditions of psoriatic disease

  2022cites this paper
• The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events

  2022cites this paper
• Safety of biological therapy in patients with rheumatoid arthritis in administrative health databases: A systematic review and meta-analysis

  2022cites this paper
• The Hypoxia-Adenosine Link during Myocardial Ischemia—Reperfusion Injury

  2022cites this paper
• Hotspots and future directions in rheumatoid arthritis-related cardiovascular disease: A scientometric and visualization study from 2001 to 2021 based on Web of Science

  2022cites this paper